Table 1.
CAR-NK-cell therapy for hematological malignacies registered in clinicaltrials.gov.
| Clinical trial identifier | Phase | Disease | Target | NK-cell source | Location |
|---|---|---|---|---|---|
| NCT02892695 | I/II | Relapsed/Refractory Leukemia and Lymphoma | CD19 | NK-92 cell line | China |
| NCT03056339 | I/II | Relapsed/Refractory B-Lymphoid Malignancies | CD19 | CB-NK cells | USA |
| NCT04555811 | I | Diffuse large or high-grade B cell lymphoma. | CD19 | hiPSC-derived NK cells (FT596) | USA |
| NCT04245722 | I | Relapsed/Refractory B-cell Lymphoma and CLL | CD19 | hiPSC-derived NK cells (FT596) | USA |
| NCT04887012 | I | Refractory/Relapsed B-cell NHL | CD19 | HLA haploidentical-NK cells | China |
| NCT04796675 | I | Relapsed/Refractory B Lymphoid Malignancies | CD19 | CB-NK cells | China |
| NCT00995137 | I | Relapsed/Refractory B-lineage ALL | CD19 | HLA haploidentical-NK cells | USA |
| NCT03690310 | Early Phase I | Relapsed/Refractory B Cell Lymphoma | CD19 | N/A | China |
| NCT04639739 | Early Phase I | Refractory/Relapsed B-cell NHL | CD19 | N/A | China |
| NCT03824964 | Early Phase I | Relapsed/Refractory B Cell Lymphoma | CD19/CD22 | N/A | China |
| NCT03692767 | Early Phase I | Relapsed/Refractory B Cell Lymphoma | CD22 | N/A | China |
| NCT02944162 | I/II | Relapsed/Refractory AML | CD33 | NK-92 cell line | China |
| NCT04623944 | I | Relapsed/Refractory AML or MDS | NKG2D | N/A | USA |
| NCT03940833 | I/II | Relapse/Refractory MM | BCMA | NK-92 cell line | China |
| NCT02742727 | I/II | Relapsed/Refractory Leukemia and Lymphoma | CD7 | NK-92 cell line | China |